临床医学工程2024，Vol.31Issue(7)：821-822,2.DOI:10.3969/j.issn.1674-4659.2024.07.0821
化疗联合芳香化酶抑制剂治疗绝经后激素受体阳性乳腺癌患者的临床效果及安全性分析
Analysis on Clinical Effect and Safety of Chemotherapy Combined with Aromatase Inhibitor in the Treatment of Patients with Postmenopausal Positive Hormone Receptor Breast Cancer
谭要鹏 1李平 1刘超颖1
作者信息
- 1. 许昌市中心医院乳腺外科,河南许昌 461000
- 折叠
摘要
Abstract
Objective To analyze the clinical effect and safety of chemotherapy combined with aromatase inhibitor in the treatment of patients with postmenopausal positive hormone receptor breast cancer.Methods 90 patients with postmenopausal positive hormone receptor breast cancer admitted to our hospital from February 2020 to June 2022 were selected and randomly divided into reference group(45 cases)and combined group(45 cases).The reference group was treated with TE(docetaxel+epirubicin)chemotherapy,and the combined group was treated with anastrozole on the basis of the reference group.The objective response rate(ORR)and the incidence of adverse reactions were compared between the two groups.Results The ORR of the combined group was 55.56%,significantly higher than 33.33%of the reference group(P<0.05).During the treatment,the incidence of adverse reactions in the combined group was 31.11%,which had no statistical difference with 37.78%in the reference group(P>0.05).Conclusions Chemotherapy combined with aromatase inhibitor in the treatment of patients with postmenopausal positive hormone receptor breast cancer,can significantly improve the clinical efficacy,but does not significantly increase the incidence of adverse reactions with higher safety.关键词
乳腺癌/激素受体阳性/芳香化酶抑制剂/化疗/临床疗效/安全性Key words
Breast cancer/Positive hormone receptor/Aromatase inhibitor/Chemotherapy/Clinical efficacy/Safety分类
医药卫生引用本文复制引用
谭要鹏,李平,刘超颖..化疗联合芳香化酶抑制剂治疗绝经后激素受体阳性乳腺癌患者的临床效果及安全性分析[J].临床医学工程,2024,31(7):821-822,2.
